Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparative Effects of Autogenic Inhibition vs Reciprocal Inhibition in Patients With Lower Cross Syndrome

18. september 2026 oppdatert av: Foundation University Islamabad

This randomized controlled trial aims to compare the effectiveness of Autogenic Inhibition Muscle Energy Technique (MET) and Reciprocal Inhibition MET in individuals with Lower Crossed Syndrome. Participants will be randomly assigned to two intervention groups. One group will receive Autogenic Inhibition MET, while the other will receive Reciprocal Inhibition MET for the iliopsoas, rectus femoris, and erector spinae muscles. Both groups will also perform the same standardized strengthening exercises targeting the transversus abdominis, gluteus maximus, and gluteus medius muscles to improve muscle balance and functional outcomes.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Participants who meet the eligibility criteria and provide informed consent will be randomly allocated into two experimental groups using a randomization method. The intervention will be carried out over a period of six weeks, with three treatment sessions per week, making a total of 18 sessions for each participant. Before the commencement of each treatment session, all participants will receive a 10-minute hot pack application over the lumbar region to promote muscle relaxation, reduce soft tissue stiffness, and prepare the muscles for manual therapy. Following the hot pack, participants will receive the assigned Muscle Energy Technique (MET) according to their respective group.

Participants in Experimental Group 1 will receive Autogenic Inhibition Muscle Energy Technique (Modified Post-Facilitation Stretch Protocol) targeting the iliopsoas, rectus femoris, and erector spinae muscles. The therapist will position the involved muscle at its initial barrier, after which the participant will perform an isometric contraction of approximately 20-30% of maximal effort for 7-10 seconds against the therapist's resistance. After relaxation, the muscle will be gently stretched to the new barrier and the stretch will be maintained for 30 seconds. This procedure will be repeated 3-5 times for each muscle during every treatment session.

Participants in Experimental Group 2 will receive Reciprocal Inhibition Muscle Energy Technique for the same muscle groups. The therapist will position the muscle at the initial barrier, and the participant will perform an isometric contraction of the antagonist muscle using approximately 20-30% of maximal effort for 7-10 seconds. Following relaxation, the therapist will move the muscle to the new barrier and maintain the stretch for 30 seconds. The technique will also be repeated 3-5 times for each targeted muscle during every treatment session.

Both groups will follow an identical strengthening exercise program to address the weak muscles commonly associated with Lower Crossed Syndrome. The strengthening program will target the transversus abdominis, gluteus maximus, and gluteus medius muscles using progressive therapeutic exercises prescribed according to the participant's tolerance. During the first two weeks, the intervention will primarily emphasize improving flexibility and reducing muscle tightness through the assigned MET. From Week 3 to Week 6, participants will continue receiving their allocated MET while simultaneously performing the strengthening exercises to restore muscle balance, improve lumbopelvic stability, and enhance functional performance. Exercise intensity and repetitions will be progressed gradually throughout the intervention while maintaining proper technique and patient comfort.

The treatment duration, session frequency, hot pack application, strengthening protocol, therapist supervision, and progression of exercises will remain identical for both groups. The only difference between the two groups will be the type of Muscle Energy Technique employed-Autogenic Inhibition MET in Experimental Group 1 and Reciprocal Inhibition MET in Experimental Group 2. Outcome measures will be recorded before and after completion of the intervention period to evaluate the comparative effectiveness of both treatment approaches in improving pain, muscle flexibility, lumbar range of motion, posture, and functional disability among individuals with Lower Crossed Syndrome.

Studietype

Intervensjonell

Registrering (Antatt)

46

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Rekruttering
        • Foundation University College of Physical Therapy
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år til 35 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  • Age 19-35 years.
  • Both genders will include in this study.
  • According to Janda's Approach, Clinical diagnosis of LCS based on ≥3 positive clinical tests.
  • Patient with positive modified Thomas test, Patients with a positive testing of prone hip extension test, Patients with a positive test of trunk flexion test, Patients with tight erector spinae muscles.
  • Participants with no lumbar pain to moderate lumbar pain (NPRS0-6) will be included.
  • Painless movement and activity.
  • Pain only produced by sustained loading in relevant position, which is then relieved after maintaining a corrected posture for 5 minutes, indicating posture-related pain.

Exclusion Criteria

  • Leg symptoms when walking, eased in flexion (Signs of stenosis)
  • Pain due to repetitive movement
  • Lumbar Radiculopathy
  • Neurological Symptoms (Paresthesia/numbness)
  • Structural deformity (Kyphosis, lordosis, scoliosis, spondylosis, spondylolysis, spondylolisthesis)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Autogenic Inhibtion (Group A)

Group A will receive Autogenic inhibition using PFS, preceded by 10 minutes heating pad application. 30% Isometric contraction(7-10 sec), followed by relaxation & 30 sec stretch, will be repeated 3-5 time. From Weeks 3-6, strenghtening exercises for hip extensors & Transverse Abdominis will be performed.

Experimental Group 1 will receive MET based on autogenic inhibition using Modified Post-Facilitation Stretch (PFS) for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction for 7-10 seconds, followed by relaxation and hip extension stretching for 30 seconds. For rectus femoris, the procedure will be performed in modified Thomas position with knee flexion, followed by hip extension and knee flexion stretching for 30 seconds. For erector spinae, subjects will sit with legs hanging and arms crossed, perform a 30% isometric contraction for 7-10 seconds, followed by trunk flexion for 30 seconds. Each technique will include 30-second rest and 3-5 repetitions. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Eksperimentell: Reciprocal Inhibition (Group B)

Group B will receive Reciprocal Inhibition using using MET,preceding by a 10 minute heating pad application. A 30% isometric contraction(7-10 sec) of antagonist muscle, followed by relaxation & 30-60sec passive stretch, will be repeated 3-5 times. From 3-6 weeks strenghening exercises for hip extensor & transverse abdominis will be performed.

Experimental Group 2 will receive MET based on reciprocal inhibition for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction of the gluteus maximus for 7-10 seconds, followed by relaxation and passive hip extension stretching for 30-60 seconds. For rectus femoris, subjects will assume modified Thomas position followed by a 30% isometric hamstring contraction for 7-10 seconds and passive stretching into hip extension with knee flexion for 30-60 seconds. For Erector Spinae, subjects will sit with legs hanging and perform a 30% isometric transverse abdominis contraction for 7-10 seconds, followed by trunk flexion for 30-60 seconds. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Lumbar Extensor Muscle Length
Tidsramme: Baseline & after 6 weeks of intervention.

The Modified Schober's Test will be used to assess lumbar extensor muscle length and lumbar spine mobility. The increase in distance between standardized spinal landmarks during maximal forward flexion will be measured and recorded in centimeters (cm). A greater increase in distance indicates greater lumbar extensor flexibility or length.

Baseline & after 6 weeks of intervention.
Functional Movement dysfunction
Tidsramme: Baseline and after 6 Weeks of intervention.

Functional Movement Screen will be used to assess functional movement dysfunction. It consists of seven tests, scored on a 0-3 scale, with a total score ranging from 0 to 21. Lower scores indicate greater movement dysfunction.

Baseline and after 6 Weeks of intervention.
Back Pain
Tidsramme: Baseline and after 6 Weeks of intervention.

Pain intensity will be assessed using the Numerical Pain Rating Scale, ranging from 0 (no pain) to 10 (worst possible pain). Participants reporting pain intensity scores of 0-6 on the NPRS will be eligible for inclusion in the study.

Baseline and after 6 Weeks of intervention.
Functional Disability
Tidsramme: Baseline and after 6 Weeks of intervention

Functional disability will be assessed using the Oswestry Disability Index (ODI), a 10-item questionnaire, with each item consisting of six response options.

Baseline and after 6 Weeks of intervention
Lumbar Range Of Motion
Tidsramme: Baseline and after 6 Weeks of invention

Lumbar spine range of motion (ROM) will be assessed using inclinometer, including lumbar flexion, extension, and lateral flexion. Lumbar ROM will be determined by measuring the difference between the readings obtained at the T12 and S2 spinal landmarks.

Baseline and after 6 Weeks of invention

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. februar 2026

Primær fullføring (Antatt)

18. desember 2026

Studiet fullført (Antatt)

18. januar 2027

Datoer for studieregistrering

Først innsendt

18. september 2026

Først innsendt som oppfylte QC-kriteriene

18. september 2026

Først lagt ut (Faktiske)

24. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • FUI/FUCP/CTR/MSMSK/MomnaKhadim

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .